EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma

On May 20, 2016, a conditional marketing authorization valid through the European Union (EU) was issued for daratumumab as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Tzogani, Kyriaki, Penninga, Elisabeth, Schougaard Christiansen, Marie Louise, Hovgaard, Doris, Sarac, Sinan B., Camarero Jimenez, Jorge, Garcia, Isabel, Lafuente, Marta, Sancho‐López, Arantxa, Salmonson, Tomas, Gisselbrecht, Christian, Pignatti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2018
Assuntos:
Regulatory Issues: EMA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947446/
https://ncbi.nlm.nih.gov/pubmed/29371479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0328
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados